EGFR and synovial sarcoma: The first test of EGFR inhibition using gefitinib and conventional chemotherapy was active in vitro and in vivo in a human fibrosarcoma cell lines [34], but a phase II clinical trial on gefitinib in EGFR-expressing EGFR-wild type advanced synovial sarcomas had low response rates and short-lived disease control [39].